Healthcare Industry News: rosuvastatin
News Release - May 5, 2008
Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZenecaStudy represents first inclusion of Volcano Revolution(R) 45 MHz IVUS Imaging Catheter in large-scale pharmaceutical plaque progression trial.
SAN DIEGO, May 5 (HSMN NewsFeed) -- Volcano Corporation (Nasdaq: VOLC ), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today participation in SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of rosuvastatin Versus AtorvastatiN). This marks the first major pharmaceutical trial allowing physicians to use the Volcano Revolution® 45 MHz IVUS Imaging catheter as part of the protocol.
SATURN is a 104-week, parallel-group, multicentre, double-blind, Phase IIIb intravascular ultrasound (IVUS) imaging study of approximately 1,300 patients at 170 centres worldwide. This study by AstraZeneca is designed to measure the impact of CRESTOR(TM) (rosuvastatin) 40 mg and atorvastatin (Lipitor®) 80 mg on the progression of atherosclerosis in high risk patients. SATURN will compare the effects of these two statins on the ability to decrease progression or induce regression of atherosclerosis, the main cause of cardiovascular disease, following two years of treatment in patients with coronary artery disease.
The SATURN study is chaired by Steve Nissen, M.D., with Steve Nichols, M.D. from the Cleveland Clinic Core Lab as the principle investigator. Under this protocol, physicians enrolling patients may select the Volcano Revolution® IVUS catheters as their IVUS catheter of choice.
About Volcano Corporation
Volcano Corporation (NASDAQ: VOLC ) offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart diseases and guide optimal therapies. The company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use phased array and rotational IVUS imaging catheters, and advanced functionality options such as VH(TM) tissue characterization and ChromaFlo®. Internal DICOM networking provided by DICOM by Merge. Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires and is developing a line of ultra high-resolution Optical Coherence Tomography systems and catheters. Currently, more than 3,200 Volcano IVUS and FM systems are installed worldwide, with approximately half of its revenues coming from outside the United States. For more information, visit the company's website at http://www.volcanocorp.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding Volcano's business that are not historical facts may be considered "forward-looking statements," including statements regarding the company's success and timing of product development and new product introductions, and market penetration, conditions and expectations. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted are detailed in the company's annual report on Form 10-K, quarterly report on Form 10-Q, and other filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano undertakes no obligation to update any forward- looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.